e-learning
resources
Milan 2017
Monday, 11.09.2017
Smoking and health hazards
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Non-small cells lung cancer (NSCLC) in non-smokers (NS) – sharing experience
R. Boaventura (PORTO, Portugal)
Source:
International Congress 2017 – Smoking and health hazards
Session:
Smoking and health hazards
Session type:
Poster Discussion
Number:
2994
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Boaventura (PORTO, Portugal). Non-small cells lung cancer (NSCLC) in non-smokers (NS) – sharing experience. 2994
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Gene expression profiles in non-small cell lung cancer (NSCLC) and lung tissue in smokers and non-smokers
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Non-small cell lung cancer in never-smokers
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Lung cancer
Source: Respipedia Article
Year: 2018
Is
MIF -173G/C
polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility?
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC)
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)?
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Differences in gene expression profiles in non-small cell lung cancer (NSCLC) and in corresponding healthy lung tissue in smokers and non-smokers
Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer
Year: 2010
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept